There are 51 resources available
LBA71 - A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)
Presenter: Xiuning Le
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1323MO - Immune evasion across space and time in patients with lung cancer enrolled in the PEACE autopsy study
Presenter: Sonya Hessey
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
658MO - Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors
Presenter: Yi-Long Wu
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1293MO - Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial
Presenter: Farastuk Bozorgmehr
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1313MO - Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy
Presenter: Benjamin Besse
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA72 - DARWIN II: Deciphering anti-tumour response and resistance to immunotherapy with intratumour heterogeneity in NSCLC
Presenter: Crispin Hiley
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1314MO - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Luis Paz-Ares
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA99 - First survival data from the NIPU trial: A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma
Presenter: Aaslaug Helland
Session: Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA61 - Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6
Presenter: Marina Garassino
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1312MO - Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)
Presenter: Enric Carcereny
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast